文献速递病毒性肝炎

三抗原乙型肝炎疫苗的3期随机临床试验:免疫原性与安全性

Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究在俄罗斯18-45岁成人中开展随机双盲对照3期试验,比较3剂方案的三抗原乙肝疫苗(3AV,10 μg)与单抗原疫苗(1AV,20 μg)。第210天3AV血清转换率100%非劣于1AV的97.9%(差值2.1%,95%CI:-2.0, 6.3%),两组血清保护率均>97%,3AV在90天和180天抗-HBs滴度显著更高,未报告严重不良事件。

要点

  • 3AV第210天血清转换率100%非劣于1AV的97.9%。
  • 两组第210天血清保护率均>97%,3AV在90天和180天抗-HBs滴度更高。
  • 局部反应率两组相似,未报告严重不良事件。

核心结论

  • 3AV对1AV非劣效,诱导高血清保护率且无安全性担忧。

研究设计与样本

  • 随机双盲对照3期试验,比较3剂3AV(10 μg)与1AV(20 μg)在18-45岁成人中的免疫原性和安全性。

主要发现

  • 第210天血清转换率3AV为100%,1AV为97.9%,差值2.1%(95%CI:-2.0, 6.3%)。
  • 第210天两组血清保护率均>97%。
  • 3AV组抗-HBs滴度在第90天(P=.001)和第180天(P=.0001)显著更高。
  • 性别、年龄和BMI对抗-HBs滴度无影响。
  • 局部反应率两组相似:首剂后30% vs 18.8%(P=.15),第二剂后20.0% vs 14.6%(P=.33),第三剂后14.9% vs 23.4%(P=.22),未报告SAEs。

关键数值与推荐

  • 主要结局为非劣效性:第210天血清转换率差值95%CI下限>-4%。
  • 血清保护率定义为抗-HBs ≥10 mIU/mL。

临床怎么用

  • 3AV可作为成人乙肝疫苗接种的替代选择,具有非劣效免疫原性和相似安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study compares the immunogenicity and safety of a 3-antigen (S/pre-S1/pre-S2) hepatitis B (HepB) vaccine (3AV), to a single antigen vaccine (1AV) in adults to support the registration of 3AV in Russia. METHODS: We conducted a randomized, double-blind, comparative study of 3-dose regimens of 3AV (10 μg) and 1AV (20 µg) in adults aged 18-45 years. We evaluated immunogenicity based on hepatitis B surface (HBs) antibody titers at days 1, 28, 90, 180, and 210, adverse and serious adverse events (SAEs) to study day 210. The primary outcome was based on the difference in rates of seroconversion at day 210 (lower bound 95% confidence interval [CI]: > - 4%). Secondary outcomes were seroprotection rates (SPR), defined as anti-HBs ≥10 mIU/mL and anti-HBs geometric mean concentration (GMC). RESULTS: Rate of seroconversion in 3AV (100%) was noninferior to 1AV (97.9%) at study day 210 (difference: 2.1%, 95% CI: -2.0, 6.3%]) but significantly higher at study day 28. SPR at study day 210 was >97% in both arms. Anti-HBs titers were significantly higher at study days 90 (P = .001) and 180 (P = .0001) with 3AV. Sex, age, and body mass index (BMI) had no impact on anti-HBs titers. The rates of local reactions related to vaccination were similar between vaccine arms (3AV vs 1AV) after the first (30% vs 18.8%, P = .15), second (20.0% vs 14.6%, P = .33), and third vaccination (14.9% vs 23.4%, P = .22). No SAEs were reported. CONCLUSIONS: 3AV was noninferior to 1AV. 3AV induced high SPR, and there were no safety concerns. Clinical Trials Registration. NCT04209400.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Esaulenko EV, Yakovlev AA, Volkov GA, et al. Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation. Clin Infect Dis. 2021. PMID: 33119068. doi:10.1093/cid/ciaa1649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。